Teva announced the launch of Levalbuterol Inhalation Solution, the generic version of Sunovion’s Xopenex Inhalation Solution. Xopenex is a beta-2 agonist indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children >6 years of age with reversible obstructive airway disease.
Levalbuterol acts as a functional antagonist to relax the airway irrespective of the spasmogen involved, thus protecting against all bronchoconstrictor challenges. Activation of beta2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylcyclase and to an increase in the intracellular concentration of cyclic AMP.
Levalbuterol Inhalation Solution is available in 0.31mg, 0.63mg, and 1.25mg strengths in 3mL vials.
For more information call (888) 838-2872 or visit the Tevagenerics website.